Pacific Edge is a New Zealand cancer diagnostics company based in Dunedin. It develops and markets urine-based molecular tests, chiefly under the Cxbladder name, which help clinicians assess patients with blood in the urine and monitor people for bladder cancer. Its customers are urologists, hospitals and healthcare providers, mainly in New Zealand and the United States, who use the tests to support decisions about further investigation and follow-up care.
On this site Pacific Edge Ltd appears as a stock on the Australian Securities Exchange (Australia), code PEB, with prices in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Fair price profile
Ranks #788 of 1815 on the Australian Securities Exchange · confidence Medium
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Australia yet.
TrendStrong
76/100
Trading above its long-term averages and near its highs.
See the numbers →
Above 200-day average-0.5%
From 52-week high-26.9%
MomentumFair
53/100
Typical recent returns for this exchange.
See the numbers →
3-month return-19.1%
6-month return8.6%
Stability (higher is calmer)Fair
57/100
Typical risk for this exchange.
See the numbers →
Volatility, 1 year (lower is calmer)88.1%
Worst drawdown, 1 year (smaller is calmer)-34.1%
LiquidityWeak
21/100
Thinly traded: prices can jump and exits can be hard.
See the numbers →
Avg daily value traded0.01M AUD
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Australia when fundamentals data for this market is added. All Australia stocks.
52-wk range 0.085 – 0.265Daily closes, split-adjusted
Signals
50-day average0.212
200-day average0.191
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.005
Technical summary
Daily
Strongly bearish
0 bullish · 4 neutral · 12 bearish
Weekly
Neutral
6 bullish · 1 neutral · 5 bearish
Monthly
Bullish
5 bullish · 1 neutral · 2 bearish
Moving averages (daily)
SMA 10
0.19
Bearish
EMA 10
0.19
Bearish
SMA 20
0.20
Bearish
EMA 20
0.20
Bearish
SMA 50
0.21
Bearish
EMA 50
0.21
Bearish
SMA 100
0.22
Bearish
EMA 100
0.21
Bearish
SMA 200
0.19
Bearish
EMA 200
0.19
Bearish
Oscillators (daily)
RSI (14)
33.19
Neutral
MACD (12, 26)
-0.01
Bearish
Momentum (12)
-13.64
Bearish
Stochastic %K (14)
25.00
Neutral
Williams %R (14)
-75.00
Neutral
CCI (20)
-96.90
Neutral
Pivot points (classic, last session)
S3
0.17
S2
0.18
S1
0.18
Pivot
0.19
R1
0.19
R2
0.20
R3
0.20
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in AUD. Educational only, not financial advice.
